US Patent 8,653,033: Scope, Claim-by-Claim Coverage, and US Landscape
United States Patent 8,653,033 claims a treatment method for severe chronic pain using an implantable intrathecal pump to deliver ziconotide (ω-conopeptide) by continuous intrathecal infusion, with an opioid (morphine or hydromorphone) administered separately, while avoiding admixture of ziconotide and the opioid in the same pump reservoir (or otherwise avoiding co-infusion/combination in the pump) to address ziconotide stability.
What is the claimed “core” invention?
The independent claim set is built around one technical premise: ziconotide stability improves when an opioid is not admixed in the pump (explicitly in claims reciting “recommending against admixing” or “not recommending admixing” ziconotide and morphine/hydromorphone). The claims also tightly couple:
- Indication: severe chronic pain in a human.
- Delivery system: implantable pump for continuous intrathecal infusion.
- Combination philosophy: ziconotide delivered intrathecally (via pump) while an opioid is administered, but the opioid is not admixed with ziconotide in the pump.
- Formulation and stability: antioxidant-containing ziconotide composition (methionine) with defined pH and stability thresholds over specified days.
This creates a narrower method space than a broad “ziconotide plus opioid therapy” patent. The method coverage turns on (i) pump admixture avoidance and (ii) specified ziconotide formulation/stability criteria.
How do the independent claims structure the method?
Claim 1 (method with ω-conopeptide + opioid, avoiding admixture)
Claim 1 recites a multi-step clinical and procedural method:
1) Select a patient with severe chronic pain who has an implantable pump.
2) Recommend against admixing an ω-conopeptide and an opioid in the pump.
3) Administer a therapeutically effective amount of ω-conopeptide (continuous intrathecal infusion using the pump).
4) Administer a therapeutically effective amount of the opioid.
Key scope levers:
- Admixture avoidance is central: the claim is not framed as “opioid is given” but as “do not admix ω-conopeptide and opioid in the pump.”
- Opioid category is limited to morphine or hydromorphone.
- ω-conopeptide is defined broadly in claim 1, then constrained later to ziconotide.
Claim 11 (method with ziconotide + opioid; tighter dose/formulation constraints)
Claim 11 is a second independent claim with stricter dosing and formulation structure:
1) Select a patient with severe chronic pain who has an implantable pump.
2) Do not recommend admixing ziconotide and morphine in the pump.
3) Administer ziconotide formulation by continuous intrathecal infusion using the pump at 0.6–27.9 μg/day, where the formulation includes methionine.
4) Administer a therapeutically effective opioid.
Scope deltas vs claim 1:
- Opioid is explicitly morphine (not hydromorphone).
- Ziconotide dose window is defined (0.6–27.9 μg/day).
- Methionine antioxidant is required in the ziconotide formulation.
- Admixture avoidance remains the mechanism.
Claim-by-Claim Coverage: What is actually protected?
Claim 2
This narrows claim 1’s opioid set to morphine for dependent coverage.
Claim 3
- Morphine daily dose is 0.6 to 4.8 μg/day.
This is a very specific opioid dosing dependent limitation.
Claim 4
- ω-conopeptide is ziconotide.
This narrows claim 1 to the marketed ω-conopeptide.
Claim 5
- Ziconotide is in a pharmaceutical composition comprising an antioxidant.
This shifts coverage from generic ziconotide to a defined formulation class.
Claim 6
- Antioxidant is methionine.
This is the strongest formulation constraint: methionine is the antioxidant.
Claim 7
- Pharmaceutical formulation pH is between 4 and 4.5.
This is a formulation parameter that can support nonobviousness and limit design-around.
Claim 8
- Stability of ziconotide is >90% for 14 days.
Claim 9
- Stability of ziconotide is >80% for 28 days.
Claim 10
- Stability of ziconotide is >80% for 32 days.
Claims 8-10 establish a stability envelope across multiple timepoints. In infringement analysis, these thresholds matter because the patent position is effectively “this formulation and this handling approach preserves stability over these periods.”
Claim 12
- Stability >90% for 14 days.
Claim 13
- Stability >80% for 32 days.
These are dependent on claim 11’s methionine + dose + admixture-avoidance structure.
Claim 14
- “Morphine is avoided to be admixed with ziconotide to enhance the stability of ziconotide.”
This is a method limitation that reinforces the technical rationale. In practice, it is still an admixture-avoidance limitation, but phrased as a stability enhancement objective.
What actions by clinicians or device operators fall within the method claims?
The operative limitation is not purely “what drug was used,” but what recommendation/handling is performed in connection with pump use:
- A workflow that includes a directive equivalent to “do not admix ziconotide and opioid in the pump” aligns with claim 1 and claim 11.
- Continuous intrathecal infusion via an implantable pump aligns with the delivery limitation.
- For dependent coverage, the formulation must include methionine and have pH 4–4.5, and the ziconotide must meet stated stability thresholds.
- The method also requires that the patient receives an opioid (morphine or hydromorphone depending on the claim set), but the opioid cannot be admixed with ziconotide in the pump.
Practically, the claim set maps best onto regimens using:
- Separate infusion sources for ziconotide and the opioid (e.g., different reservoirs/pumps, or procedural separation that avoids mixing inside the pump).
- A ziconotide formulation that meets methionine/pH/stability thresholds.
How narrow or broad is this patent compared with the clinical category?
This patent is narrower than broad combination-therapy patents for two reasons:
1) Admixture avoidance in the pump is mandatory
The claims do not merely require that a clinician administers ziconotide and an opioid; they require a recommendation not to admix them in the pump.
2) Formulation and stability limits exist in key dependent layers
Methionine antioxidant, pH 4–4.5, and explicit stability percentages over days create a narrower claim scope for commercial embodiments that might otherwise use a different antioxidant system, different pH, or accept lower stability.
At the same time, the claims are not extremely narrow because:
- Claim 1 does not require methionine or pH or stability thresholds; it requires avoidance of admixture and intrathecal infusion of ω-conopeptide with opioid administration.
- That allows more coverage where the clinical handling meets the “do not admix in pump” concept even if the specific methionine/pH/stability embodiment is not used, at least for the portions of the claim set not limited by dependent features.
Infringement pressure points (design-around levers)
The claim structure points to several high-leverage design-around strategies for competitors and formulators:
1) Mixing policy
- The claims hinge on “recommend against admixing … in the pump.”
- If a regimen mixes ziconotide and morphine/hydromorphone in the pump but maintains stability, the “avoid admixture” limitation is directly implicated.
2) Drug identity
- Claim 2 limits opioid to morphine; claim 1 allows morphine or hydromorphone.
- A strategy using a different opioid would fall outside the enumerated opioid group.
3) Formulation system
- Methionine antioxidant and pH 4–4.5 are required for dependent claims 5–7.
- If a product uses a different antioxidant or a different pH, dependent coverage may weaken.
4) Stability performance
- Dependent claims 8–10 and 12–13 require explicit stability thresholds at specified day counts.
- A formulation that fails those thresholds would not infringe those dependent claims.
US Patent Landscape Context: how this claim strategy sits among ziconotide IP
This patent sits at the intersection of two IP clusters:
- Ziconotide formulation and stability (commonly addressed through excipients, pH control, antioxidants, and shelf/storage stability).
- Intrathecal pump delivery and compatibility (often addressing whether co-administered agents can be placed in the same reservoir or whether separate handling is required).
The distinctive element is that it claims a clinical method with an admixture-avoidance instruction and ties it to stability outcomes via methionine/pH/stability-dependent claims.
Practical landscape impact for portfolio decisions
- If a company’s ziconotide program depends on co-formulation or co-loading with morphine/hydromorphone in the same pump reservoir, this patent increases risk in the US method space because claim 1 and claim 11 directly target admixture avoidance.
- If the company uses separate reservoirs or procedural separation aligned with “do not admix in the pump,” the risk shifts from independent claim 1/11 toward dependent formulation/stability claim exposure, depending on the exact formulation and stability.
What is the “scope of claims” in business terms?
-
Independent coverage (Claims 1 and 11) protects clinical pump-based ziconotide treatment protocols that:
- deliver ziconotide (or an ω-conopeptide) intrathecally via an implantable pump, and
- do not admix ziconotide and a specified opioid in the pump, while still administering the opioid to the patient.
-
Dependent coverage (Claims 5–10, 12–13) protects specific ziconotide formulation characteristics:
- methionine antioxidant,
- pH 4 to 4.5,
- ziconotide stability thresholds exceeding defined percentages at defined day counts.
-
Dependent coverage (Claims 2–3, 14) further constrains:
- opioid selection (morphine),
- opioid dose band in claim 3,
- explicit avoidance of morphine admixture to enhance stability.
Key Takeaways
- US 8,653,033 is a pump-delivery method patent for severe chronic pain combining ziconotide intrathecal infusion with an opioid, while prohibiting admixture of ziconotide and the opioid in the pump (central limitation).
- Independent claims 1 and 11 cover the clinical handling/recommendation concept; dependent claims add methionine antioxidant, pH 4–4.5, and stability thresholds.
- The primary commercial risk driver is whether a regimen co-loads or admixes ziconotide with morphine/hydromorphone in the pump reservoir rather than using separate handling.
- The primary technical risk driver for formulators is whether the ziconotide formulation matches methionine/pH and meets the stability thresholds in the dependent claims.
FAQs
1) Does the patent cover “ziconotide plus opioid” generally?
No. The independent claims require avoidance of admixing ziconotide and the specified opioid in the pump and require continuous intrathecal infusion using the implantable pump.
2) Which opioid(s) are covered?
Claim 1 covers morphine or hydromorphone; claim 11 and several dependents focus on morphine.
3) Are methionine and pH required to infringe?
Not for the independent claim scope, but they are required for dependent claims 5–7 (methionine antioxidant and pH 4–4.5) and for dependent stability claims that build on the methionine formulation.
4) Are the stability thresholds tied to storage or to an in-use time period?
The claims state stability percentages over day counts (for example, >90% for 14 days and >80% for 28 or 32 days) but do not, in the provided claim text, specify the condition context beyond “stability of ziconotide.”
5) What is the easiest design-around lever?
Align dosing/handling so that ziconotide and morphine/hydromorphone are not admixed in the pump, and, for dependent claim exposure, use a ziconotide formulation outside the methionine/pH and stability thresholds.
References
[1] United States Patent 8,653,033, claims as provided by user.
